Alexion Pharmaceuticals, Inc. has announced that the US Food and Drug Administration (FDA) has approved Soliris (eculizumab) as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody-positive.
Indications: Soliris demonstrated treatment benefits for patients with anti-AchR antibody-positive gMG who had previously failed immunosuppressive treatment and continued to suffer from significant unresolved disease symptoms, which can include difficulties seeing, walking, talking, swallowing, and breathing. These patients are at an increased risk of disease exacerbations and crises that may require hospitalization and intensive care and may be life-threatening. They represent approximately 5-10% of all patients with MG.
Dosage/administration: For patients with gMG, Soliris therapy consists of 900 mg weekly for the first 4 weeks, followed by 1,200 mg for the fifth dose 1 week later, then 1,200 mg every 2 weeks thereafter. Soliris should be administered at the recommended dosage regimen time points, or within 2 days of these time points.
Adverse reactions: In patients with gMG who are anti-AchR antibody-positive, the most frequently reported adverse reaction observed in the placebo-controlled clinical study (≥10%) was musculoskeletal pain.
FDA approves Soliris (eculizumab) for the treatment of patients with generalized myasthenia gravis (gMG). [news release]. New Haven, Connecticut: Alexion Pharmaceuticals, Inc. October 23, 2017. http://news.alexion.com/print/node/699. Accessed October 30, 2017.
This Week's Must Reads
Sex Differences Evident in Cognitive Decline in PD, Parkinsonism Relat Disord; ePub 2018 Feb 9; Cholerton, et al
IBD Associated with Lower Risk of Developing PD, Parkinsonism Relat Disord; ePub 2018 Feb 9; Camacho-Soto, et al
Dysgeusia, Side Effect of DBS, Can Be Reduced, J Clin Neurosci; ePub 2018 Feb 2; Carlson, et al
Leg Stereotypy Syndrome Common in Healthy Adults, J Neuro Neurosurg Psychiatry; ePub 2018 Jan 13; Lotia, et al
Adductor Focal Laryngeal Dystonia Impacts QOL, J Clin Mov Disord; ePub 2017 Dec 13; Stewart, et al
Must Reads in FDA Actions
Riptide Aspiration System Receives FDA Clearance, Medtronic news release; 2018 Jan 16
FDA Approves Vercise Deep Brain Stimulation System, Boston Scientific news release; 2017 Dec 11
FDA Approves Repatha to Prevent Stroke, Heart Attack, Amgen news release; 2017 Dec 1
FDA Clears Apple Watch Heart Rate Accessory, PharmaLive news release; 2017 Nov 30
FDA Approves Oral Option for Pediatric Epilepsy, UCB news release; 2017 Nov 6